학술논문
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Document Type
Article
Author
Abraham, Sonya; Juel, Helene B; Bang, Peter; Cheeseman, Hannah M; Dohn, Rebecca B; Cole, Tom; Kristiansen, Max P; Korsholm, Karen S; Lewis, David; Olsen, Anja W; McFarlane, Leon R; Day, Suzanne; Knudsen, Sara; Moen, Kjersti; Ruhwald, Morten; Kromann, Ingrid; Andersen, Peter ; Shattock, Robin J; Follmann, Frank
Source
In The Lancet Infectious Diseases October 2019 19(10):1091-1100
Subject
Language
ISSN
1473-3099